GOOD MORNING

Here’s everything you need to know today: There are currently 14,157 publicly traded companies in the United States and over 1000+ articles released about S&P500 companies alone every single day. Today we will be showing you our top 3 stock picks we have hand picked for this week:

1 year performance

1. TUYA - 96%

2. AKRO - 209%

3. PL - 182%

This Week (Here’s our top 3 stock picks)  

1. Tuya Inc. (TUYA)

1 Year Performance: +96%

Category: Momentum

Market Cap: $2.1B

Company Info:

Tuya Inc. is a global IoT (Internet of Things) platform that provides cloud-based solutions, AI, and connectivity services to help manufacturers, brands, and developers create and manage smart devices. The company enables smart home, smart business, and industrial applications by offering a unified platform for device control, data analytics, and interoperability across different ecosystems.

Why it’s a buy:

Tuya Inc. is a buy due to its strong positioning in the rapidly growing IoT market, providing essential cloud-based AI solutions for smart devices across multiple industries.

With the increasing adoption of smart home technology, industrial automation, and AI-driven ecosystems, Tuya benefits from high demand and scalability.

The company reported $81.6 million in revenue for Q3 2024, marking a 33.6% year-over-year increase, driven by a 26.4% rise in IoT platform-as-a-service (PaaS) revenue and over 100% growth in its smart solutions segment.

Its partnerships with global manufacturers and recurring revenue model from cloud services enhance long-term growth potential.

Additionally, its low valuation relative to future growth prospects and improving financial performance make it an attractive investment for those looking to capitalize on the expanding IoT and smart technology sectors.

Revenue:

2. Akero Therapeutics Inc. (AKRO)

1 Year Performance: +209%

Category: Momentum

Market Cap: $4.1B

Company Info:

Akero Therapeutics is a clinical-stage biotechnology company focused on developing treatments for metabolic diseases with high unmet medical needs. Its lead drug candidate, efruxifermin (EFX), is designed to treat nonalcoholic steatohepatitis (NASH), a serious liver disease, by improving liver health, reducing fibrosis, and addressing underlying metabolic dysfunction.

Why it’s a buy:

Akero Therapeutics is a buy due to its recent breakthrough in treating metabolic dysfunction-associated steatohepatitis (MASH).

In a Phase 2b trial, their lead drug candidate, efruxifermin (EFX), demonstrated that 39% of patients with compensated cirrhosis experienced a reversal of liver scarring after 96 weeks, compared to 15% in the placebo group.

This unprecedented result led to a significant increase in the company's stock price, reflecting strong investor confidence.

Analysts have responded positively, with nine out of nine issuing a "Buy" rating and an average 12-month price target of $75.86, suggesting a potential upside of over 38% from the current price.

These factors highlight Akero's promising position in addressing a critical unmet medical need.

1 Year Chart:

3. Planet Labs PBC (PL)

1 Year Performance: +182%

Category: Growth

Market Cap: $1.8B

Company Info:

Planet Labs PBC is a private Earth imaging company that operates a large fleet of satellites, providing daily, high-resolution imagery of the planet. Its data is used by organizations across various sectors, including agriculture, energy, and environmental monitoring, for applications like resource management, disaster response, and climate research.

Why it’s a buy:

Planet Labs PBC is considered a buy due to its strong position in the Earth imaging market and recent positive analyst evaluations.

The company has secured significant contracts, including a seven-year, $230 million agreement with an Asia-Pacific commercial partner, enhancing its revenue streams and market presence.

Analysts have responded favorably, with Benchmark increasing its price target to $7 from $4, reflecting confidence in Planet Labs' growth prospects.

The stock has demonstrated robust performance, reaching a 52-week high of $6.55, indicating investor optimism.

With a consensus "Strong Buy" rating and an average 12-month price target of $5.74, analysts anticipate potential upside from the current price.

Revenue:

Get more picks like Planet Labs…

If you are interested in receiving more of our top stock picks like Planet Labs sign up to our Elite Membership where you get access to:

• The ability to choose which stocks you want to receive (value stocks, dividend stocks, momentum stocks, etc.)

• 3 curated emails a week (monday, wednesday, friday) with 2 hand-picked stocks from your chosen category in each email

• 1 report a week (sunday) on the general market and state of where the stock market is it currently

• Direct email contact with myself to ask any questions regarding stock knowledge

• Exclusive offers from any of our partners (trade software, brokers, news sources, etc.)

• 2 week money back guarantee (100% refund)

Join today for only $4.99/month or $44.99/year. 

Otherwise, stay tuned for our next free release at 8:15 am EST (Monday and Friday).

Free Stock Picks every Monday and Friday…

We send out our Crown weekly Free newsletter every Monday and Friday. If you are interested in receiving these emails then congratulations, you are all signed up. If not, then click the unsubscribe button at the bottom of this email.

What to expect:

• You will receive an email every Monday and Friday with 3 stock picks that Crown has hand picked. These can include (momentum stocks, trending stocks, value stocks, and more.)

This is completely FREE and will be sent directly to your inbox every Monday and Friday. 

Our Partners:

The #1 Trading Software in the world: Tradingview 

Thank you for your time!

I’m sure you get hundreds of emails a day so I thank you for taking the time to read ours. Please follow us on our social media channels below where we post other new and different content related to investing, personal finance, and trading. 

Stay tuned for our next free release at 8:15 am EST (Monday and Friday).